Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Director · President and CEO | May 19, 2026 | May 21, 2026 |
| TURMERIC ACQUISITION CORP.TMPM · Entity 139875 | Director | October 15, 2020 | October 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 497,503 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Gift · Disposed 160,000 · Balance 497,503 F1: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 160,000 |
Reported balance
After 2026-05-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-19 · Gift · Acquired 160,000 · Balance 160,000 F1: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes.
TURMERIC ACQUISITION CORP.
Report date October 15, 2020 · Filed October 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARRAY BIOPHARMA INC
Report date July 30, 2019 · Filed July 30, 2019
Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-07-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-30 · Disposition to issuer · Disposed 71,022 · Balance 130,542 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 130,542 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-30 · Disposition to issuer · Disposed 12,500 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on March 2, 2016. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2025-04-01 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-30 · Disposition to issuer · Disposed 236,250 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on April 1, 2016. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-04-01 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-30 · Disposition to issuer · Disposed 236,250 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7: The option provided for vesting in four equal annual installments beginning on April 1, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2026-12-27 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-07-30 · Disposition to issuer · Disposed 313,989 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F8: The option provided for vesting in four equal annual installments beginning on December 26, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.92 · Expires 2027-12-16 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-30 · Disposition to issuer · Disposed 335,250 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F9: The option provided for vesting in four equal annual installments beginning on December 16, 2018. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.97 · Expires 2028-12-16 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-07-30 · Disposition to issuer · Disposed 315,750 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F10: The option provided for vesting in four equal annual installments beginning on December 16, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
F4: The option provided for vesting in four equal annual installments beginning on March 2, 2016.
F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.
F6: The option provided for vesting in four equal annual installments beginning on April 1, 2016.
F7: The option provided for vesting in four equal annual installments beginning on April 1, 2017.
F8: The option provided for vesting in four equal annual installments beginning on December 26, 2017.
F9: The option provided for vesting in four equal annual installments beginning on December 16, 2018.
F10: The option provided for vesting in four equal annual installments beginning on December 16, 2019.
Harpoon Therapeutics, Inc.
Report date March 11, 2024 · Filed March 11, 2024
Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 1
1 source rowRow 1 · 2024-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.10 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-11 · Disposition to issuer · Disposed 1,016 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-11 · Disposition to issuer · Disposed 2,300 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock").
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the
F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 20:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GiftCommon Stock | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234578 · ownership.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 160,000 F1 · kind: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GiftCommon Stock | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234578 · ownership.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,503 F1 · kind: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 245,000 | $0.00 Strike: $39.45 | $0.00 |
DisclosureSEC source: 0001193125-25-326775 · ownership.xml · derivative · entry 4 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 245,000 shares Expires 2035-12-17 F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | Tax withholdingCommon Stock | 367,497 | $39.45 | $14,497,756.65 |
DisclosureSEC source: 0001193125-25-326775 · ownership.xml · nonDerivative · entry 3 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 657,503 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 840,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326775 · ownership.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,025,000 F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs"). Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 185,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326775 · ownership.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:56 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 915,000 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0000950170-25-009257 · ownership.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915,000 Underlying: Common Stock · 915,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 21:18 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 2,300 | Not disclosed Strike: $6.66 | Not disclosed |
DisclosureSEC source: 0000950170-24-029433 · ownership.xml · derivative · entry 3 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · price: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · derivative.exercise_date: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · derivative.expiration_date: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 21:18 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,016 | Not disclosed Strike: $20.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-029433 · ownership.xml · derivative · entry 2 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,016 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · price: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · derivative.exercise_date: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · derivative.expiration_date: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 21:18 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Disposition to issuerCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-029433 · ownership.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2 · shares: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). F3 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). F1 · acquired: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:20 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,100,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000950170-24-007414 · ownership.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100,000 Underlying: Common Stock · 1,100,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| November 27, 2023 Filed Nov 28, 2023 21:28 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056798 · doc4.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock issuable upon the settlement of restricted stock units ("RSUs"). 25% of the RSUs will vest on each May 27th and November 27th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:38 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001209191-23-039420 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on June 21, 2024, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 20:49 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 525,000 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0000899243-23-005135 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 22:49 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-22-039328 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2032-06-21 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on June 21, 2023, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 22:37 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 690,000 | $4.94 Strike: $7.60 | $3,410,808.00 |
DisclosureSEC source: 0000899243-22-003462 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,000 Underlying: Common Stock · 690,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| May 04, 2021 Filed May 8, 2021 01:57 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001209191-21-031108 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2031-05-03 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 4, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| May 04, 2021 Filed May 15, 2021 00:05 UTC Amendment | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $23.20 | $0.00 |
DisclosureSEC source: 0001209191-21-032965 · doc4a.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2031-05-03 F1 · derivative.exercise_price: This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error. F2 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 3, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. The original Form 4 filed on May 7, 2021 erroneously reported this vesting date as May 4, 2022. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:17 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 315,200 | $0.00 Strike: $10.17 | $0.00 |
DisclosureSEC source: 0000899243-21-006403 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,200 Underlying: Common Stock · 315,200 shares Expires 2031-02-10 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 02:09 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 456,693 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0000899243-20-033232 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,693 Underlying: Common Stock · 456,693 shares Expires 2030-12-07 F1 · derivative.exercise_date: This stock option shall vest over a four year period as follows: 1/4th of the option shall vest one year after the vesting start date; then 1/48th of the option shall vest monthly over the remaining three year period. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 20:05 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 7,442,421 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001209191-20-055909 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,442,421 Underlying: Common Stock · 7,442,421 shares Expires 2030-10-22 F1 · derivative.exercise_date: This stock option shall vest as follows: 25% on the first anniversary of the date of grant; then in equal monthly installments over 36 months. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 21:18 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (right to buy) · Derivative | 20,335 | $0.00 Strike: $11.78 | $0.00 |
DisclosureSEC source: 0001209191-20-022193 · doc4.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,335 Underlying: Common Stock · 20,335 shares Expires 2030-03-29 F1 · derivative.exercise_date: The stock option vests in three equal annual installments measured from the date of grant, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:04 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 315,750 | Not disclosed Strike: $15.97 | Not disclosed |
DisclosureSEC source: 0001209191-19-043782 · doc4.xml · derivative · entry 8 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 315,750 shares Expires 2028-12-16 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F10 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 16, 2019. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:04 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 335,250 | Not disclosed Strike: $10.92 | Not disclosed |
DisclosureSEC source: 0001209191-19-043782 · doc4.xml · derivative · entry 7 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 335,250 shares Expires 2027-12-16 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F9 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 16, 2018. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:04 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 313,989 | Not disclosed Strike: $8.79 | Not disclosed |
DisclosureSEC source: 0001209191-19-043782 · doc4.xml · derivative · entry 6 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 313,989 shares Expires 2026-12-27 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F8 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on December 26, 2017. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:04 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 236,250 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001209191-19-043782 · doc4.xml · derivative · entry 5 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 236,250 shares Expires 2026-04-01 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on April 1, 2017. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:04 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 236,250 | Not disclosed Strike: $7.30 | Not disclosed |
DisclosureSEC source: 0001209191-19-043782 · doc4.xml · derivative · entry 4 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 236,250 shares Expires 2025-04-01 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on April 1, 2016. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:04 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | Not disclosed Strike: $8.20 | Not disclosed |
DisclosureSEC source: 0001209191-19-043782 · doc4.xml · derivative · entry 3 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2025-03-02 F5 · price: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4 · derivative.exercise_date: The option provided for vesting in four equal annual installments beginning on March 2, 2016. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:04 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerCommon Stock | 130,542 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043782 · doc4.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3 · price: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. Read SEC document |
| July 30, 2019 Filed Jul 30, 2019 20:04 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerCommon Stock | 71,022 | $48.00 | $3,409,056.00 |
DisclosureSEC source: 0001209191-19-043782 · doc4.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,542 F1 · kind: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2 · kind: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:31 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 9,844 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-002184 · primarydocument.xml · derivative · entry 4 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,844 Underlying: Common Stock · 9,844 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The RSUs vest and will be settled in stock in four equal installments beginning April 1, 2016. F4 · derivative.expiration_date: The RSUs vest and will be settled in stock in four equal installments beginning April 1, 2016. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:31 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 9,844 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-002184 · primarydocument.xml · derivative · entry 3 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,844 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The RSUs vested and settled in stock in four equal installments beginning April 1, 2015. F3 · derivative.expiration_date: The RSUs vested and settled in stock in four equal installments beginning April 1, 2015. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:31 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 8,660 | $24.60 | $213,036.00 |
DisclosureSEC source: 0001562180-19-002184 · primarydocument.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,022 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:31 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 19,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-002184 · primarydocument.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on April 1, 2015 and April 1, 2016, as a result of the vesting of one fourth of such RSUs. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 18:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001562180-19-000862 · primarydocument.xml · derivative · entry 5 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,500 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on April 1, 2015. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 18:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001562180-19-000862 · primarydocument.xml · derivative · entry 4 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 37,500 shares Expires 2025-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 2, 2016. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 18:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 239,626 | $20.03 | $4,798,510.65 |
DisclosureSEC source: 0001562180-19-000862 · primarydocument.xml · nonDerivative · entry 3 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,994 F1 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $20.00 to $20.20. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 18:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 87,500 | $4.63 | $405,125.00 |
DisclosureSEC source: 0001562180-19-000862 · primarydocument.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 18:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 37,500 | $8.20 | $307,500.00 |
DisclosureSEC source: 0001562180-19-000862 · primarydocument.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 13,968 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-005029 · primarydocument.xml · derivative · entry 6 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,907 Underlying: Common Stock · 13,968 shares Expires 2021-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 13,083 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-005029 · primarydocument.xml · derivative · entry 5 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,166 Underlying: Common Stock · 13,083 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 11,898 | $15.97 | $190,011.06 |
DisclosureSEC source: 0001562180-18-005029 · primarydocument.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,620 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 27,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-005029 · primarydocument.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 315,750 | $0.00 Strike: $15.97 | $0.00 |
DisclosureSEC source: 0001562180-18-005029 · primarydocument.xml · derivative · entry 4 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,750 Underlying: Common Stock · 315,750 shares Expires 2028-12-16 F4 · derivative.exercise_date: The options vest in four equal annual installments beginning on December 16, 2019. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 52,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-005029 · primarydocument.xml · derivative · entry 3 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,625 Underlying: Common Stock · 52,625 shares Expires 2022-12-20 F3 · derivative.exercise_date: RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 16:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 32,068 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003130 · primarydocument.xml · derivative · entry 4 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,068 shares Expires 2018-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: RSUs representing 32,068 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 16:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 17,964 | $17.74 | $318,681.36 |
DisclosureSEC source: 0001562180-18-003130 · primarydocument.xml · nonDerivative · entry 3 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,467 F3 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $17.60 to $17.84. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 16:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 14,104 | $18.50 | $260,924.00 |
DisclosureSEC source: 0001562180-18-003130 · primarydocument.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,431 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 16:22 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 32,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003130 · primarydocument.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares released on vesting of Restricted Stock Units ("RSUs") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 18:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 9,844 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001801 · primarydocument.xml · derivative · entry 3 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,688 Underlying: Common Stock · 9,844 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The remaining RSUs vest and will be settled in stock in two equal annual installments on April 1, 2019 and 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.